| Biomarker ID | 760 |
| PMID | 21963599 |
| Year | 2012 |
| Biomarker | OPNa (osteopontin -a ) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Cancerous Conditions (PCA: Median: 62.43; BPH: Median: 0.20) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Alpha-V beta-3 integrin/OPN pathway,TWEAK regulation of gene expression,Osteopontin signaling,Osteoclast signaling,Beta-3 integrin cell surface interactions |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Specimens were obtained from 40 PCa and 30 benign prostate hyperplasia (BPH) patients |
| Senstivity | 62.5% |
| Specificity | 96.7% |
| AUC | 0.74 |
| Accuracy | 77.1% |
| Level Of Significance | p<0.05 |
| Method Used | Quantitative real time PCR (qRT-PCR) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SPP1 |